El síndrome metabólico como factor de riesgo cardiovascular

Villar Álvarez, 2003 Boix, 2003, Mortalidad cardiovascular en España. Año 2000, Boletín Epidemiológico Semanal, 11, 241 Organizacion Mundial de la Salud. Los objetivos de la salud para todos. Estrategia regional europea. Madrid: OMS; 1986. Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94 Daniels, 2005, Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment, Circulation, 111, 1999, 10.1161/01.CIR.0000161369.71722.10 Kissebah, 1994, Regional adiposity and morbidity, Physiol Rev, 74, 761, 10.1152/physrev.1994.74.4.761 Ridker, 2004, High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit, Am Heart J, 148, S19, 10.1016/j.ahj.2004.04.028 Reaven, 2002, Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease, Circulation, 106, 286, 10.1161/01.CIR.0000019884.36724.D9 Vega, 2001, Results of expert meetings: obesity and cardiovascular disease. Obesity, the metabolic syndrome, and cardiovascular disease, Am Heart J, 142, 1108, 10.1067/mhj.2001.119790 Zanchetti, 2001, Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study, J Hypertens, 19, 819, 10.1097/00004872-200104000-00020 Fruchart JC. International symposium on PPARs (peroxisome proliferator activated receptors): from basic science to clinical applications. Kluwer Academic: Giovanni Lorenzini Medical Foundation; 2002. Medical Science Symposia Series, 18. Hu, 2004, Prevalence of the metabolic syndrome and its relation to allcause and cardiovascular mortality in nondiabetic European men and women, Arch Intern Med, 164, 1066, 10.1001/archinte.164.10.1066 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. Lakka, 2002, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288, 2709, 10.1001/jama.288.21.2709 Klein, 2002, Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam, Diabetes Care, 25, 1790, 10.2337/diacare.25.10.1790 Solymoss, 2004, Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity, Am J Cardiol, 93, 159, 10.1016/j.amjcard.2003.09.032 Alexander, 2003, NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Kip, 2004, Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study, Circulation, 109, 706, 10.1161/01.CIR.0000115514.44135.A8 Olijhoek, 2004, The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm, Eur Heart J, 25, 342, 10.1016/j.ehj.2003.12.007 Resnick, 2003, Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study, Diabetes Care, 26, 861, 10.2337/diacare.26.3.861 Hernández Mijares, 2003, Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica, Med Clin (Barc), 121, 204, 10.1157/13049916 Gimeno Orna, 2004, Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2, Rev Esp Cardiol, 57, 507, 10.1157/13062916